Interventional × Myelodysplastic-Myeloproliferative Diseases × fludarabine phosphate × Clear all
NCT02861417 2026-02-17

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
204 enrolled
NCT02727803 2025-11-06

Personalized NK Cell Therapy in CBT

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
NCT00544115 2025-06-10

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

City of Hope Medical Center

Phase 2 Active not recruiting
260 enrolled 13 charts
NCT00003816 2021-08-13

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

Roswell Park Cancer Institute

Phase 2/3 Completed
361 enrolled 16 charts
NCT00054236 2020-07-27

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

Case Comprehensive Cancer Center

Phase 1 Completed
55 enrolled
NCT00068523 2020-07-27

Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

Case Comprehensive Cancer Center

Phase NA Completed
10 enrolled
NCT01527045 2020-01-02

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

Fred Hutchinson Cancer Center

Phase 2 Completed
47 enrolled 18 charts
NCT00085449 2019-11-27

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Alliance for Clinical Trials in Oncology

Phase 1/2 Withdrawn
NCT00044954 2019-09-17

Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

University of Texas Southwestern Medical Center

Phase 2 Completed
NCT00245037 2017-09-27

Bu Flu TBI

OHSU Knight Cancer Institute

Phase 1/2 Completed
147 enrolled 19 charts
NCT00281879 2017-09-27

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

OHSU Knight Cancer Institute

Phase 2 Terminated
200 enrolled 11 charts
NCT00691015 2017-06-28

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
48 enrolled 12 charts
NCT00719849 2017-06-14

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Fred Hutchinson Cancer Center

Phase 2 Terminated
13 enrolled 24 charts
NCT00075478 2017-05-15

Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 3 Completed
87 enrolled 16 charts
NCT01118013 2017-03-24

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Alliance for Clinical Trials in Oncology

Phase 2 Terminated
6 enrolled 5 charts
NCT00104975 2016-12-15

Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Yale University

Phase 1 Completed
20 enrolled
NCT00255684 2016-11-03

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

University of Rochester

Phase NA Terminated
16 enrolled 6 charts
NCT00800150 2015-06-08

Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

City of Hope Medical Center

Phase 1 Terminated
6 enrolled
NCT00589563 2014-09-10

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

City of Hope Medical Center

Phase 2 Completed
32 enrolled 24 charts
NCT00295997 2014-01-06

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

National Cancer Institute (NCI)

Phase NA Unknown
35 enrolled
NCT00005863 2013-12-19

Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
NCT00818961 2013-12-18

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer

Northside Hospital, Inc.

Phase 2 Terminated
36 enrolled 16 charts
NCT00066417 2013-05-01

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

National Cancer Institute (NCI)

Phase 2 Terminated
51 enrolled
NCT00627666 2013-03-26

Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled
NCT00301912 2012-10-02

Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

University of California, San Francisco

Phase 2 Withdrawn
NCT00787761 2012-10-01

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Northside Hospital, Inc.

Phase 2 Completed
24 enrolled 13 charts
NCT00080925 2012-03-08

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
20 enrolled
NCT00006379 2011-12-08

Non-Ablative Allo HSCT For Hematologic Malignancies or SAA

Case Comprehensive Cancer Center

Phase 2 Completed
58 enrolled
NCT00806767 2011-05-17

Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer

National Cancer Institute (NCI)

Phase 2 Completed
82 enrolled
NCT00055653 2011-03-07

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Roswell Park Cancer Institute

Phase 2 Completed
NCT00053287 2010-06-10

Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS

Case Comprehensive Cancer Center

Phase 2 Completed
42 enrolled
NCT00346359 2010-05-14

Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
40 enrolled
NCT00006042 2010-03-10

Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed